Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing epidemiological studies and mechanistic hypotheses without systematic search criteria or primary data analysis.
PubMed 36759741 · doi:10.1038/s41582-023-00775-5
What was done
This narrative review synthesizes epidemiological and mechanistic evidence linking Epstein-Barr virus (EBV) infection to multiple sclerosis (MS). It examines longitudinal risk data, underlying biological mechanisms of EBV-induced pathogenesis, and translational implications for MS prevention and therapy (such as vaccines and antiviral agents).
What was found
The abstract notes that MS risk is minimal in EBV-seronegative individuals but increases over 30-fold following EBV infection. It highlights established associations between MS risk and both infectious mononucleosis and high anti-EBV antibody titers, framing MS as a rare complication of a virus that infects over 90% of the global population. No other numerical data or statistical effect sizes are reported in the abstract.
Why it matters
Establishing EBV as an essential causal trigger clarifies MS etiology and focuses therapeutic and preventive strategies on EBV-targeted interventions, including prophylactic vaccines and antivirals.
Limits
The review relies on previously published observational data rather than presenting new empirical findings. It lacks a systematic review methodology or study quality assessment. While EBV infection appears necessary for MS development, it is not sufficient on its own given that over 90% of the population is infected, indicating other genetic or environmental co-factors remain unmeasured in this abstract.
Cited by
- partial Epstein-Barr virus is causally implicated in triggering Hashimoto's thyroiditis and multiple sclerosis.